NCT06249282 2026-04-03
Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer
City of Hope Medical Center
Phase 1 Recruiting
Clinical Trials
14 trialsNCT05896228 2026-03-11
Iber-KDd
University of Miami
Phase 2 Recruiting
NCT03909412 2026-02-18
CarMob
Hackensack Meridian Health
Phase 1 Recruiting
NCT05199311 2026-02-18
Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma
Hackensack Meridian Health
Phase 1/2 Recruiting
NCT06627751 2026-01-12
Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease
Roswell Park Cancer Institute
Phase 2 Recruiting
NCT05789303 2025-12-22
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
University of Chicago
Phase 2 Recruiting
NCT04176718 2025-10-07
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Massachusetts General Hospital
Phase 2 Recruiting
NCT05620238 2025-08-21
Home Treatment With Carfilzomib in Patients With Multiple Myeloma
Odense University Hospital
Recruiting
NCT06409702 2025-06-12
Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
The First Affiliated Hospital of Soochow University
Phase 4 Recruiting
NCT06140966 2025-04-16
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Recruiting
NCT06622005 2025-04-16
SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Roswell Park Cancer Institute
Phase 1 Recruiting
NCT04513639 2025-03-20
The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study
Oslo University Hospital
Phase 2/3 Recruiting
NCT06879379 2025-03-17
KPD Consolidation After ASCT in NDMM Patients
Peking University People's Hospital
Phase 2/3 Recruiting
NCT05060627 2022-09-08
Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide
PETHEMA Foundation
Phase 1/2 Recruiting